Bernard Courtieu, CEO of IntegraGen, is interviewed by EEI – Biotech for Finance. Mr. Courtieu discusses IntegraGen’s role in the sequencing of liver tumors as a part of a recent publication announcing the identification of a new virus involved in the development of liver cancer. 

Integragen genomics sequencing clinicalThe interview is conducted by Jacques -Bernard Taste, Editorial Director, Biotech Finances/Biotech Transactions.

Click here to listen to the interview.

Please note that the interview and text are available in French only.